CES Unveiled in Amsterdam Highlights Tech Improving Lives
17.10.2019 19:09:00 EEST | Business Wire | Press release
The Consumer Technology Association (CTA) ® today made several announcements at CES Unveiled in Amsterdam, an official CES® 2020 preview event. Executives, influential media and prominent industry influencers gathered at the record-breaking event to celebrate the latest European innovations and experience what to expect at CES 2020.
CTA announced that eight companies from the Netherlands and the surrounding region were announced as CES 2020 Innovation Honorees. Best of Innovation honorees include Dutch company Hydraloop Systems BV in the Sustainability, Eco-Design & Smart Energy category and British company Valerann in the Smart Cities category.
“Europe is a hotbed for innovation consistently driving our industry forward and we saw the promise and power of technology at CES Unveiled in Amsterdam,” said Karen Chupka, EVP, CES. “CES 2020 will showcase the most innovative tech from Europe that truly has the potential to make people’s lives better.”
The remaining honorees will be revealed at CES Unveiled in Paris on Oct. 22., 2019, and CES Unveiled New York on Nov. 7, 2019. Honorees will be posted online at CES.tech starting Nov. 7, 2019 and many will showcase their winning products at CES 2020, Jan. 7-10, in Las Vegas.
In its third year, CES Unveiled in Amsterdam set records by selling out exhibit space and bringing together more than 1,500 attendees from nearly 50 countries. The event also featured government and industry leaders from the Netherlands and surrounding regions including, Pete Hoekstra, U.S. Ambassador to the Netherlands; Mona Keijzer, Netherlands State Secretary for Economic Affairs and Climate Policy; Femke Halsema, Mayor of Amsterdam; and Corinne Vigreux, co-founder of TomTom and founder of CODAM.
Europe welcomed more than 16,000 attendees to CES 2019 and continues to lead innovation by example. The European Union had a strong presence at CES Unveiled in Amsterdam, featuring leaders including, Katerina Borunska, Policy Officer, European Commission; Hubert Cottogni, Director, Head of Mandate Management, European Investment Fund; and Els Sweeney-Bindels, Head of EIB Amsterdam Office, European Investment Bank. CES Unveiled promotes the continued value it shares with Europe through partnerships across government, business and research.
TechLeap.NL also announced their new visual identity and the 50 startups they are bringing to CES 2020 as part of Eureka Park. HRH Prince Constantijn van Oranje, Special Envoy at TechLeap.NL, also discussed why CES is important for Dutch startups and why he is working to make the Netherlands the best place for tomorrow’s leaders in technology.
Owned and produced by CTA, CES 2020, the world’s largest and most influential tech event, will run Jan. 7-10, 2020, in Las Vegas, NV and provide access to the most transformative tech across various marketplaces, such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, vehicles, digital health and more. Industry leaders and rising stars will come together again to pioneer future innovation driving the ever-evolving tech industry.
Registration for CES 2020 is now open. For the latest exhibitor news and show announcements, visit CES.tech.
About CES:
CES® is the largest, most influential tech event in the world – the proving ground for breakthrough technologies and global innovators. This is where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. Owned and produced by the Consumer Technology Association (CTA)®, CES features every aspect of the tech sector. Learn more at CES.tech and follow CES on social.
About Consumer Technology Association:
As North America’s largest technology trade association, CTA® is the tech sector. Our members are the world’s leading innovators – from startups to global brands – helping support more than 18 million American jobs. CTA owns and produces CES® – the largest, most influential tech event on the planet. Find us at CTA.tech. Follow us @CTAtech.
UPCOMING EVENTS
-
CES Unveiled in Paris
October 22 – Paris, France -
Consumer Technology Hall of Fame
November 6, 2019 – New York, NY -
CES Unveiled New York
November 7 – New York, NY -
CES Unveiled Las Vegas
January 5, 2020 – Las Vegas, NV -
CES 2020
January 7-10, 2020 – Las Vegas, NV
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005692/en/
Contact information
Justin Siraj
703-907-7415
jsiraj@CTA.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
